Web Analytics
หุ้น NTRA (NASDAQ) | NATERA INC – วิเคราะห์โดย Deepscope
MARKET

Select Market Data Region

NTRA — NATERA INC (Healthcare >> Diagnostics & Research)

NTRA FAQ

What is NTRA's P/E ratio?

NATERA INC (NTRA) currently trades at a P/E ratio of 655.07.

What is NTRA's ROE?

NATERA INC reports a Return on Equity (ROE) of -12.76%.

What is NTRA's dividend yield?

NATERA INC offers a dividend yield of 0.00%.

What is NTRA's Deepscope Quality Score?

Deepscope rates NTRA's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy NTRA?

Deepscope's AI Timing Score for NTRA is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does NTRA belong to?

NATERA INC is classified under the Healthcare >> Diagnostics & Research sector on the NASDAQ exchange.

Stock Check   *ข้อมูลอัปเดตรายวัน ที่เวลา 09.30 น.*
(Price: 2026-06-08 | FS: 2026-03-31)

NTRA

NATERA INC
USD 213.47
-1.84 (-0.85%) Day Change
655.07
P/E
0.05
D/E
-12.8%
ROE
-8.7%
ROA
0.00%
Div Yield
-21.37
PEG
USD 213.47
Price
-1.84 (-0.85%)
Day Change
NEWS SCORE: 84

NTRA มีคุณภาพโดยรวมไม่ดี ( คะแนนปัจจัยพื้นฐาน = 31) แต่ จังหวะเข้าซื้อ ...(ล็อกอินเพื่อดู)...

31

QUALITY

Signal
UNDERPERFORM
Signal Description
Company financial health is Not Good
Reason
P/E ratio ค่อนข้างสูง
อัตราผลตอบแทนผู้ถือหุ้น (ROE) ค่อนข้างต่ำ
อัตราผลตอบแทนสินทรัพย์ (ROA) ค่อนข้างต่ำ
อัตราเร่งของการเติบโตของอัตราผลตอบแทนผู้ถือหุ้น (ROE) ต่ำกว่าเกณฑ์
อัตราผลตอบแทนผู้ถือหุ้น (ROE) ในอดีต ค่อนข้างต่ำ
อัตราผลตอบแทนสินทรัพย์ (ROA) ค่อนข้างต่ำเมื่อเทียบกับอัตราผลตอบแทนผู้ถือหุ้น(ROE)
อัตราเร่งของการเติบโตของอัตราผลตอบแทนสินทรัพย์ (ROA) ต่ำกว่าเกณฑ์
อัตรากำไรสุทธิ ค่อนข้างต่ำ
อัตราเร่งของการเติบโตของอัตรากำไรสุทธิ ต่ำกว่าเกณฑ์
อัตรากำไรสุทธิในอดีต ค่อนข้างต่ำ

88 Sign in

TIMING

Signal
OUTPERFORM
Signal Descri...
Good
Reason
Lorem ipsum dolor sit amet
Sign in to see timing analysis
Unlock timing signals and detailed reasons
Sign in free

ถ้าดูอย่างละเอียดจะพบว่า ปัจจัยทางคุณภาพ ไม่ดี สุขภาพทางการเงิน ไม่ดี และ ประสิทธิภาพการทำกำไร ยังไม่ดีนัก , ...

ปัจจัยทางคุณภาพ 39%
X
X
X
X
  In Recommendations? Not in any sections
  Select Rate 0.00 From 30 days period
  Watch Rate 0.00 From 30 days period
  News Score 84
  Magic Formula Rank by ROA
N/A
  Magic Formula Rank by ROE
N/A
  Magic Formula Rank by ROIC
N/A
  Price 213.47
  PBV / Sector
17.45 / -23.32
  Earning Per Share -1.56
  PE / Sector
655.07 / 37.41
  PEG or PE/Growth / Sector
-21.37 / 1.39
  Average 1M Daily Value
315.50 M
GREAT
  Average 1W Daily Value
252.28 M
GREAT
ปัจจัยทางเทคนิค 57%
  MACD
  MACD Signal
  MACD Divergence
  RSI
  Stochastic Oscillator K
  Stochastic Oscillator D
  ADX
  Avg 5 day Timing Score
สุขภาพทางการเงิน 45%
X
X
X
X
  DE / Sector
  DE Average / Sector
  DE Change Average (%) / Sector
  Current Ratio / Sector
  Current Ratio Average / Sector
  Current Ratio Change Average (%) / Sector
  Quick Ratio / Sector
  Quick Ratio Average / Sector
  Quick Ratio Change Average (%) / Sector
  FCF/Share / Sector
  FCF/Share Average / Sector
  FCF/Share Change Average (%) / Sector
ประสิทธิภาพการทำกำไร 56%
X
X
X
X
X
X
X
  GPM (%) / Sector
  GPM Average (%) / Sector
  GPM Change Average (%) / Sector
  OPM (%) / Sector
  OPM Average (%) / Sector
  OPM Change Average (%) / Sector
  NPM (%) / Sector
-9.05 / 12.69
  NPM Average (%) / Sector
-27.25 / 7.99
  NPM Change Average (%) / Sector
-32.81 / -5.21
  Asset Turnover / Sector
  Asset Turnover Average / Sector
  Asset Turnover Change Average (%) / Sector
  ROA (%) / Sector
-8.66 / 11.23
  ROA Average (%) / Sector
-19.57 / -82.28
  ROA Change Average (%) / Sector
-27.13 / 159.98
  ROE (%) / Sector
-12.76 / -86.57
  ROE Average (%) / Sector
-35.06 / -2.21
  ROE Change Average (%) / Sector
-29.38 / -44.18
  ROIC (%) / Sector
  ROIC Average (%) / Sector
  ROIC Change Average (%) / Sector
ผลตอบแทนต่อผู้ถือหุ้น 4%
X
  Dividend (%) / Sector
N/A / 0.26
  Dividend Average (%) / Sector
N/A / 1.20
  Dividend Change Average (%) / Sector
N/A / 7.14
รายละเอียดการจดทะเบียน
X
  Analyze Date 2026-06-09 09:39:28
  Symbol NTRA
  Name NATERA INC
  Sector Healthcare >> Diagnostics & Research
  Market NASDAQ
  Listed Shares 143.22 M
  Par Value N/A
  Calculated From Quarter
  Sign N/A
  Market Cap (M.USD) / Sector Average 30,957.44 / 31,712.01
ข่าว, ประมาณการ, ...
  Estimation Consensus See at WSJ.com
  Full details See at WSJ.com
  Chart See in Chart feature
  News See at Yahoo Finance

Address: 13011 McCallen Pass, Austin, TX, United States, 78753

Phone: 650 980 9190

Website: https://www.natera.com

Employees: 6,135

Sector: Healthcare >> Diagnostics & Research

Description: Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in Januar

ME vs SECTOR Healthcare >> Diagnostics & Research

NTRA (ME)
Sector Peers
Bubble size = Market Cap

Click a bubble to view stock details  ·  Bubble size represents market capitalization share

News

Smart picks. Just WOW stocks/funds/ETFs. No noise like other tools.
NTRA
NTRA
USD 213.47 (-0.85%)
+ Watch + Port Chart